Recombinant Human EPO Protein，His

Recombinant erythropoietin (EPO) is a glycoprotein hormone that plays a critical role in erythropoiesis, the process of red blood cell production. Initially identified in the late 20th century, EPO was found to be a key regulator of red blood cell formation in response to hypoxic conditions. The clinical significance of EPO became apparent with the recognition of its potential for treating anemia, particularly in patients undergoing chemotherapy, those with chronic kidney disease, and individuals with various medical conditions leading to reduced red blood cell counts. The advent of recombinant DNA technology facilitated the production of EPO in laboratory settings, leading to the development of biosynthetic forms of the hormone that could be administered therapeutically. This breakthrough allowed for greater availability and purity of EPO, overcoming the limitations of traditional extraction from human or animal sources. Ongoing research focuses on optimizing EPO formulations, understanding its broader biological effects, and minimizing potential side effects, including excessive polycythemia or cardiovascular complications. Additionally, the use of EPO doping in sports has raised ethical concerns, prompting investigations into regulatory measures and detection methods. Overall, recombinant EPO has transformed the management of anemia and continues to be a subject of extensive research aimed at improving its therapeutic applications and ensuring safe administration.